Alliances
The deal has a value of over one billion dollars, with highlights for Xencor including receiving a $100 million upfront payment, a $25 million equity investment, eligibility for plamotamab royalties and potential milestone payments worth up to $1.18 billion.
The deal’s termination was announced Thursday, months after bintrafusp alfa failed to hit the mark in a Phase II clinical trial as a potential second-line treatment for metastatic biliary tract cancer.
The companies said the collaboration recognizes a “great need for novel treatments in the area of neuropsychiatric medicine development.”
The Phase II trial, VLA150202, evaluated the safety and immunogenicity of VLA15 on 246 healthy adults aged 18 to 65 years old across the United States.
AstraZeneca aims to harness VaxEquity’s saRNA platform for use with its own therapeutic programs and intends to widely use it on up to 26 different drug targets.
Nektar collaborates with Pfizer and Merck KGaA, Darmstadt, Germany, to assess NKTR-255 in combination with Bavencio in patients with bladder cancer.
During the past two years, fundraising and investment in biotechnology have reached record levels.
The massive genetic data mining project aims to gain deeper insight into how human genetic variants affect risk for common complex diseases.
Vifor Pharma Group and Travere Therapeutics inked a collaborationfor the commercialization of sparsentan for the treatment rare progressive kidney diseases.
Moderna will leverage AbCellera’s AI-powered technology to search and analyze natural immune responses in the hopes of identifying antibodies for up to six targets.
PRESS RELEASES